Stock of the Day

July 12, 2021

Danaher (DHR)

$213.90
-$2.17 (-1.0%)
Market Cap: $151.89B

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Danaher Bull Case

Here are some ways that investors could benefit from investing in Danaher Co.:

  • Danaher Co. reported a strong earnings per share (EPS) of $1.94 for the latest quarter, exceeding analysts' expectations, which indicates robust financial performance and potential for future growth.
  • The company has shown a year-over-year revenue increase of 5.5%, reflecting its ability to grow and adapt in a competitive market.
  • With a net margin of 15.95%, Danaher Co. demonstrates effective cost management and profitability, which can lead to higher returns for investors.
  • Analysts project an EPS of 8.53 for the current fiscal year, suggesting continued growth and profitability, which can be attractive for long-term investors.
  • The current stock price is around $228.91, which is close to the consensus target price, indicating that the stock may be fairly valued and could offer stability in the market.

Danaher Bear Case

Investors should be bearish about investing in Danaher Co. for these reasons:

  • Some analysts have downgraded their ratings on Danaher Co., indicating a potential lack of confidence in its short-term performance.
  • The stock has seen price target reductions from various brokerages, which may suggest that analysts are cautious about the company's growth prospects in the near future.
  • With a return on equity of 11.04%, while positive, it may not be as high as some investors expect from leading companies in the sector, indicating room for improvement.
  • Market volatility could impact Danaher Co.'s stock performance, as external economic factors may affect investor sentiment and stock prices.
  • Despite recent growth, the competitive landscape in the life sciences and diagnostics sectors remains intense, which could pose challenges for Danaher Co.'s market share and profitability.
← Previous Stock of the DayNext Stock of the Day →

Recent News